New strategies for blood donor screening for hepatitis B virus: nucleic acid testing versus immunoassay methods.
about
Hepatitis B: the virus and diseaseMolecular mechanisms underlying occult hepatitis B virus infection.Transfusion-associated infections: 50 years of relentless challenges and remarkable progress.Hepatitis B virus infections and risk factors among the general population in Anhui Province, China: an epidemiological studyImpact of nucleic acid testing for hepatitis B virus, hepatitis C virus, and human immunodeficiency virus on the safety of blood supply in Italy: a 6-year survey.Occult hepatitis B virus infection among blood donors in ColombiaCriteria for hepatitis B virus screening and validation of blood components in Italy: the position of the SIMTI HBV working group.Efficacy of the confidential unit exclusion option in blood donors in tehran, iran, determined by using the nucleic Acid testing method in 2008 and 2009.Virome Analysis of Transfusion Recipients Reveals a Novel Human Virus That Shares Genomic Features with Hepaciviruses and PegivirusesHepatitis B in Ghana: a systematic review & meta-analysis of prevalence studies (1995-2015)Hepatitis B virus infection among first-time blood donors in Italy: prevalence and correlates between serological patterns and occult infectionMolecular testing in the diagnosis and management of chronic hepatitis BSignificance of anti-HBc only in blood donors: a serological and virological study after hepatitis B vaccination.Role of molecular diagnostics in the management of viral hepatitis B.Diagnostic markers for hepatitis virus infection.Molecular mechanisms underlying HBsAg negativity in occult HBV infection.Wide variation in estimates of global prevalence and burden of chronic hepatitis B and C infection cited in published literature.Early Detection of Circulating Antigen and IgM-Associated Immune Complexes during Experimental Mycobacterium bovis Infection in Cattle.Anti-HBc screening in Egyptian blood donors reduces the risk of hepatitis B virus transmission.Hepatocellular carcinoma as an emerging morbidity in the thalassemia syndromes: A comprehensive review.Cytokine and chemokine responses in the acute phase of hepatitis B virus replication in naive and previously vaccinated blood and plasma donors.Enhancement of PCR Detection Limit by Single-Tube Restriction Endonuclease-PCR (RE-PCR).Occult Hepatitis Infection in Transfusion Medicine: Screening Policy and Assessment of Current Use of Anti-HBc TestingDevelopment of a sensitive enzyme-linked immunosorbent assay for detection of hepatitis B surface antigen using novel monoclonal antibodies.What is the role of serology for the study of chronic hepatitis B virus infection in the age of molecular biology?The efficacy of individual-donation and minipool testing to detect low-level hepatitis B virus DNA in Taiwan.Hepatitis B and residual risk of infection in English and Welsh blood donors, 1996 through 2008.Significance of screening antibodies to hepatitis B virus core antigen among Syrian blood donors.Hepatitis B virus transfusion risk in China: proficiency testing for the detection of hepatitis B surface antigen.Correlation of improved hepatitis B surface antigen detection limits with hepatitis B virus DNA nucleic acid test yield in blood donations.Hepatitis B virus blood screening: impact of nucleic amplification technology testing implementation on identifying hepatitis B surface antigen non-reactive window period and chronic infections.A novel hepatitis B virus surface antigen immunoassay as sensitive as hepatitis B virus nucleic acid testing in detecting early infection.Hepatitis B virus DNA-positive, hepatitis B surface antigen-negative blood donations intercepted by anti-hepatitis B core antigen testing: the Canadian Blood Services experience.Impact of a policy to permit the return of donors repeat-reactive to the Abbott PRISM antibody to hepatitis B core antigen assay.Quantitative estimate of the risks and benefits of possible alternative blood donor deferral strategies for men who have had sex with men.Hepatitis B virus Genotypes in West Azarbayjan Province, Northwest Iran.Current incidence and estimated residual risk of transfusion-transmitted infections in donations made to Canadian Blood Services.Significant background rates of HBV and HCV infections in patients and risks of blood transfusion from donors with low anti-HBc titres or high anti-HBc titres with high anti-HBs titres in Japan: a prospective, individual NAT study of transfusion-traCurrent incidence and residual risk of hepatitis B infection among blood donors in the United States.Study of hepatitis B prevalence in parallel with the most frequent HBV genotype in South Iranian blood donors.
P2860
Q24642704-3E388EF4-DB73-461E-A9E6-913F6A281AC4Q27686923-65D37DD9-EE9E-47BA-BF13-CCD9712B7051Q34133145-A6105D1B-7057-41CD-A1AF-94F3B77CDD6CQ34220009-05053521-C902-4E3B-BE45-DA3EF204D015Q34594321-2BA5F5B8-F551-4E4F-9A35-6AC6751DDBC6Q34636134-6AE8A3C1-DB91-44C8-89D0-0DF9C8C36E3CQ35434455-70203876-AF21-47BA-9251-50C8A800E199Q35714789-5BC06407-6530-464B-89F7-6092672A2E1FQ35784419-8EAC35D2-4DB2-49F8-96EF-C418DA1D531EQ35961475-F9A62E7C-9AC6-4EE7-B204-F7775C3324D8Q36766479-7A476BC1-EC6B-46B5-BA6E-0081C94AC061Q36881140-45FF217C-B2BD-46BD-AC03-14936F3E6576Q37602298-CF11E0F1-A6D2-428A-8252-9322FBBD96DCQ38088408-B51273C2-1E03-4490-903B-D69892170AB0Q38089735-F4A0AF0E-86C1-4EA9-B6D4-4FCF5CBAD3E3Q38536404-72D8A169-9467-4E61-8C77-B8CC08CDD047Q38793776-5315009A-C4C2-41E0-B93D-705711F7EE7CQ38839557-20143374-FED9-4B94-98FE-CF6600077F2BQ38990467-16CB703A-403A-4760-9B5D-9200CDCC5BD5Q39027102-28B9C2C8-B5CC-4D86-87DF-5719F15F7BF3Q39783525-B6A40937-6092-4C02-BA2D-6BF9143B85DEQ40844678-40352DAF-074F-472B-8135-9A607D6FB87FQ41111337-56EB1641-C320-4DE8-A4E5-7AB7418AAAD1Q41769166-37F995F8-B94F-40B5-B48A-398223181D68Q42167570-72AB7BA1-E0E4-44B7-868D-799D2EAF7C3EQ42990388-BD88D8B3-108C-4498-97FC-DCC821DBD2E1Q43851125-680468D4-A477-4576-86FB-D58A818F13F1Q43881624-02368F54-EE9E-4FE7-B281-BC92EEE973BAQ44247554-6FD54BE4-C09E-4478-B00D-1185AA68DD33Q45359766-FFD2FA09-7A1C-4FDE-A74A-426594B1B796Q45373828-18C2FC88-F196-47AA-8281-D9BA4C937E37Q45386833-B227877B-6D1F-4698-9909-5F7C786F0C0FQ45400010-4361A5FB-0F6D-4E6F-AEDF-41A90B5BED45Q46004376-B9BC422D-BE27-46E9-A86E-4C981D2B122BQ46589701-88C7E705-E80C-4CF7-AF5A-7B8994A22B60Q47549502-0175836E-393F-4AA2-8F1D-984A7B6D2BEAQ48081521-676A04D1-D471-48CA-ADC9-EEC696F73C07Q50522754-E921429F-AB96-460F-B5E5-ED49A63F87F7Q50609667-E2B33C2D-EF3A-4A79-8BF2-D5FF9ACB58A2Q51198020-34B7EC1C-5199-4B43-A0F1-340C82D574F9
P2860
New strategies for blood donor screening for hepatitis B virus: nucleic acid testing versus immunoassay methods.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh
2006年學術文章
@zh-hant
name
New strategies for blood donor ...... ng versus immunoassay methods.
@ast
New strategies for blood donor ...... ng versus immunoassay methods.
@en
type
label
New strategies for blood donor ...... ng versus immunoassay methods.
@ast
New strategies for blood donor ...... ng versus immunoassay methods.
@en
prefLabel
New strategies for blood donor ...... ng versus immunoassay methods.
@ast
New strategies for blood donor ...... ng versus immunoassay methods.
@en
P2860
P356
P1476
New strategies for blood donor ...... ng versus immunoassay methods.
@en
P2093
Mary C Kuhns
P2860
P2888
P356
10.1007/BF03256447
P577
2006-01-01T00:00:00Z